Aprea Therapeutics Reports Q1 Results, Extends Cash Runway to Q1 2028, and Updates on Clinical Trials

summarizeSummary

Aprea Therapeutics reported Q1 2026 financial results, confirming a cash runway into Q1 2028 following a recent $30 million private placement, which significantly mitigates prior going concern risks. The company also provided positive clinical updates for its WEE1 inhibitor, APR-1051, including a confirmed partial response and expanded trial enrollment.

check_boxKey Events

• Cash Runway Extended to Q1 2028

  The company reported $46.5 million in cash and cash equivalents as of March 31, 2026, and anticipates this will fund operations into the first quarter of 2028. This significantly improves financial stability and directly addresses the 'going concern' doubt previously disclosed.

• Positive Clinical Data for APR-1051

  The Phase 1 ACESOT-1051 trial for WEE1 inhibitor APR-1051 observed two partial responses, with one confirmed in a uterine carcinosarcoma patient. Enrollment is expanding to include at least 50 patients with uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer.

• Upcoming ASCO 2026 Presentation

  Additional clinical data from the ACESOT-1051 trial will be presented at the ASCO 2026 Annual Meeting on May 30, 2026, providing further insight into APR-1051's clinical profile.

• Strategic Pause for ATRN-119 Monotherapy

  The company has paused further monotherapy enrollment for its ATR inhibitor, ATRN-119, to explore potential combination approaches with academic institutions, including with radiation in HPV+ head and neck cancer.

auto_awesomeAnalysis

This filing is highly important as Aprea Therapeutics has significantly improved its financial viability, extending its cash runway into Q1 2028. This directly addresses the 'going concern' doubt and Nasdaq delisting risk previously disclosed in the company's 10-K filing on March 16, 2026. The confirmed partial response for APR-1051 and expanded enrollment in the ACESOT-1051 trial also provide positive clinical momentum, with further data expected at ASCO 2026.